PMID- 21692695
OWN - NLM
STAT- MEDLINE
DCOM- 20111004
LR  - 20220311
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Linking)
VI  - 10
IP  - 6
DP  - 2011 Jun
TI  - Heat shock protein-peptide complex in the treatment of glioblastoma.
PG  - 721-31
LID - 10.1586/erv.11.49 [doi]
AB  - Vaccination immunotherapies offer the promise of long-term tumor control, and 
      preclinical trials have found promising results. Active immunotherapy uses the 
      adaptive immune response to specifically kill tumor cells. Tumor-specific 
      antigens are processed by antigen-presenting cells and recognized by specific 
      effector lymphocytes. However, basic vaccination strategies with tumor lysates 
      have been unsuccessful in inducing antiglioma immunity in clinical trials. 
      Gliomas are known to modulate the activity of antigen-presenting cells to reduce 
      antitumor immune activity. Recently, tumor-derived heat shock proteins have been 
      found to more effectively activate the immune response. Widely expressed, heat 
      shock proteins are thought to present protein peptide fragments in a format 
      conducive to processing by antigen-presenting cells. As a part of the protein 
      synthesis machinery, peptides complexed with heat shock proteins are effectively 
      representative of antigens expressed by the cell; these peptides convey the 
      specificity of this vaccination strategy. The heat shock protein-peptide vaccine 
      is one of many promising immunotherapeutic strategies being evaluated in clinical 
      trials. These can be broadly classified as active, passive and adoptive, each 
      with advantages and disadvantages. Here, we compare and contrast heat shock 
      protein-peptide vaccines with other immunotherapies and describe the outcomes of 
      clinical trials to date.
FAU - See, Alfred P
AU  - See AP
AD  - Department of Neurosurgery, The Johns Hopkins Hospital, Baltimore, MD, USA.
FAU - Pradilla, Gustavo
AU  - Pradilla G
FAU - Yang, Isaac
AU  - Yang I
FAU - Han, Seunggu
AU  - Han S
FAU - Parsa, Andrew T
AU  - Parsa AT
FAU - Lim, Michael
AU  - Lim M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigens, Neoplasm/*immunology
MH  - Cancer Vaccines/*administration & dosage/*immunology
MH  - Glioblastoma/*therapy
MH  - Heat-Shock Proteins/*immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Peptides/*immunology
EDAT- 2011/06/23 06:00
MHDA- 2011/10/05 06:00
CRDT- 2011/06/23 06:00
PHST- 2011/06/23 06:00 [entrez]
PHST- 2011/06/23 06:00 [pubmed]
PHST- 2011/10/05 06:00 [medline]
AID - 10.1586/erv.11.49 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2011 Jun;10(6):721-31. doi: 10.1586/erv.11.49.